DGAP-Adhoc: MOLOGEN AG receives approval for clinical study with cell-based gene therapy against renal cancer

| Source: EQS Group AG EQS Group AG 

MOLOGEN AG / Miscellaneous

22.06.2010 16:42 

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Berlin, June 22 2010 - The Berlin-based biotechnology company MOLOGEN AG
has received approval from the responsible German health authority, the
Paul-Ehrlich-Institut, to carry out a phase I/II clinical study with its
innovative new MGN1601 cancer medicine. MGN1601 is a cell-based gene
therapy for the treatment of advanced renal cancer.

The responsible ethics committee has also agreed to the execution of the
study.

It is intended that the study will be carried out at 3 different study
centers in Germany and will be led by PD Dr. Steffen Weikert. The
participating study centers will be the Charité in Berlin, the University
clinic in Bonn and the Hannover Medical School. According to current plans,
the study is likely to start in the fourth quarter of the year, when all
preparations have been completed.

MOLOGEN AG
Contact: Jörg Petraß
E-mail: investor@mologen.com
Telephone: +49-30-84 17 88-13
Fax: +49-30-84 17 88-50


Kirchhoff Consult AG
Dr. Kay Baden
E-mail: baden@kirchhoff.de
Telephone: +49 40 60 91 86 39









22.06.2010 16:42 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]

---------------------------------------------------------------------------
 
Language:     English
Company:      MOLOGEN AG
              Fabeckstraße 30
              14195 Berlin
              Deutschland
Phone:        030 / 841788-0
Fax:          030 / 841788-50
E-mail:       info@mologen.com
Internet:     www.mologen.com
ISIN:         DE0006637200
WKN:          663720
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, München, Düsseldorf, Stuttgart, Hamburg
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------